Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M201-A Phase I Multiple Dose Study
NCT04464681Phase 1Completed
- Sponsor
- Kitasato University
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF), Atrial fibrillation (AFib) and chronic kidney disease (CKD) comparing M201-A Injection with Placebo (2 arms). Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability. Started Mar 2020; status: completed.
02
Drugs
m201-a
03
Conditions
heart failure (HF)Atrial fibrillation (AFib)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04464681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464681.